Literature DB >> 10395490

Self-immolative anthracycline prodrugs for suicide gene therapy.

I Niculescu-Duvaz1, D Niculescu-Duvaz, F Friedlos, R Spooner, J Martin, R Marais, C J Springer.   

Abstract

Four novel potential prodrugs derived from daunorubicin (8, 10) and doxorubicin (12, 14) were designed and synthesized. They are self-immolative prodrugs for suicide gene therapy activation by the enzyme carboxypeptidase G2 (CPG2) subsequently releasing the corresponding anthracyclines, by a 1,6-elimination mechanism. A mammary carcinoma cell line (MDA MB 361) was engineered to express CPG2 intracellularly (CPG2) or extracellularly, tethered to the outer cell membrane (stCPG2(Q)3). The prodrugs derived from doxorubicin showed prodrug/drug cytotoxicity differentials of 21-fold (compound 12) and 23-fold (compound 14). Prodrug 12 underwent an 11-fold activation when assayed in the cell line expressing externally surface-tethered CPG2.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10395490     DOI： 10.1021/jm980696v

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

Authors:  A Nagy; A Plonowski; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 3.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

4.  Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.

Authors:  Karolin Roemhild; Helena C Besse; Bi Wang; Quim Peña; Qingxue Sun; Daiki Omata; Burcin Ozbakir; Clemens Bos; Hans W Scheeren; Gert Storm; Josbert M Metselaar; Haijun Yu; Ruth Knüchel-Clarke; Fabian Kiessling; Chrit T W Moonen; Roel Deckers; Yang Shi; Twan Lammers
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

Review 5.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy.

Authors:  Yoshiyuki Yoneda; Sebastian C J Steiniger; Katerina Capková; Jenny M Mee; Ying Liu; Gunnar F Kaufmann; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2008-01-19       Impact factor: 2.823

7.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003

8.  Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

Authors:  Zheng-Hong Peng; Ying Xie; Yan Wang; Jing Li; David Oupický
Journal:  Mol Pharm       Date:  2017-01-30       Impact factor: 4.939

9.  A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.

Authors:  R A Spooner; F Friedlos; K Maycroft; S M Stribbling; J Roussel; J Brueggen; B Stolz; T O'Reilly; J Wood; A Matter; R Marais; C J Springer
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.